Tesamorelin and Belly Fat: What the Research Actually Shows

Two kinds of belly fat, two different questions

The reduction was clearest in visceral fat. For fat under the skin, the pooled trials found no statistically significant benefit over placebo.[1]

Tesamorelin acts through hormone signals. It prompts the pituitary gland, a small gland beneath the brain, to release growth hormone. That affects how the body handles fat and raises IGF-1, another hormone involved in growth. These signals act throughout the body.[2]

What the main trials actually measured

The pooled analysis included 806 participants who received treatment or placebo. All had HIV and excess abdominal fat and were taking antiretroviral therapy (ART), medicines that control HIV. About 85% were men. Researchers compared scans and other measurements over 26 weeks.[1]

The trials focused on people with HIV because tesamorelin was being tested for HIV-associated lipodystrophy. This condition changes how the body stores fat and can cause a buildup around the abdominal organs. Researchers enrolled people with HIV who had this excess fat to test the treatment in the group it was intended to help.[1][2][9]

A CT scan uses X-rays to make cross-sectional images of the body. Researchers measured the area occupied by visceral fat in an abdominal slice. The percentages below show how much that measured area changed.

You may see the pooled result described as a 15.4% reduction versus placebo. Here is where that number comes from: the treated group fell 13.1%, while the placebo group rose 2.3%. The gap between those changes is 15.4 percentage points. The average decline within the treated group was still 13.1%.[1]

The waist result gives the scan finding some everyday context. Average waist size fell by 2.4 cm—just under an inch—with tesamorelin, compared with 0.8 cm with placebo. That gives a sense of the average waist change over about six months.

Why the scale can barely move

A scale adds up everything: fat, muscle, water, bone and other tissue. Visceral fat is only one part of that total. A scan can show a change in body composition even when body weight changes little.

In the pooled trials, fat in the trunk fell while measured lean body mass rose. “Lean mass” includes muscle, water and other fat-free tissue. Changes in these different parts can offset one another on the scale.[1][3]

This is why the U.S. prescribing information describes tesamorelin as weight neutral and says it is not indicated for weight-loss management. Its approved use is to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.[2]

What about people without HIV?

There is human evidence beyond HIV. One randomized trial enrolled 60 adults with abdominal obesity and a reduced growth-hormone response to a stimulation test—a test designed to prompt hormone release. Participants were free of HIV and diabetes. Their obesity and reduced growth-hormone response are important when considering who these results apply to.[3]

After one year, visceral-fat area had fallen by about 8% in the tesamorelin group and risen by about 11% with placebo. The often-quoted 19% treatment effect describes the gap between those changes; the treated group’s own decline was about 8%.

The study found no significant benefit over placebo for body weight or fat under the skin. Only 36 of the 60 enrolled participants completed the full year, which adds uncertainty to the findings. The result is encouraging for research on visceral fat outside HIV, though evidence in healthy, lean adults remains limited.[3]

How long did it take—and what happened after stopping?

The main trials measured the result after 26 weeks—roughly six months. That is the clearest time point for judging the size of the effect.

The studies followed some participants for another 26 weeks. Those who continued tesamorelin generally maintained their visceral-fat reduction. Those switched to placebo regained much of the lost visceral fat; in the pooled withdrawal group, the average measurement was close to its original baseline by week 52.[1][4]

In these trials, keeping the reduction largely depended on continuing treatment.

The risks that belong beside the results

Tesamorelin changes more than a fat measurement. The prescribing information highlights several effects that matter when weighing the research:[2]

• Blood sugar can rise. Glucose intolerance or diabetes may develop. By 26 weeks in the clinical trials, 5% of treated participants reached an HbA1c of at least 6.5%, compared with 1% on placebo. HbA1c reflects average blood sugar over several months.
• IGF-1 can rise above the normal range. The label calls for monitoring; the effects of prolonged elevations are uncertain.
• Fluid retention can cause swelling or joint discomfort. Injection-site reactions and allergic reactions are also reported.

The label says tesamorelin must not be used during pregnancy, with active cancer, with certain conditions that disrupt the brain–pituitary hormone pathway, or with a known allergy to tesamorelin or its ingredients. Long-term cardiovascular safety remains uncertain, and whether the fat reduction leads to fewer heart attacks or longer life is still an open question.[2]

Formulation matters too. Current EGRIFTA WR and EGRIFTA SV products have different preparation and dosing instructions and are not substitutable. The clinical evidence applies to the tested drug formulations; a research-use-only vial has no established clinical equivalence to them. When reading a product’s lab report, look at what was tested: identity, purity, amount and sterility answer separate questions. WPA’s guide to reading a peptide COA explains what each test can answer.[2][5]